Heparin induces mobilization of osteoprotegerin into the circulation

Thrombosis and Haemostasis

Volumn 98, Issue 1, 2007, Pages 148-154

  Vik, Anders ^a   Brodin, Ellen ^a   Sveinbjørnsson, Baldur ^a   Hansen, John Bjarne ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Dalteparin; LMWH; Osteoporosis; Osteoprotegerin; UFH

Indexed keywords

ANTIXARIN; DALTEPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; OSTEOPROTEGERIN;

ABSENCE OF SIDE EFFECTS; ADULT; ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; BLEEDING; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MEGADOSE; HUMAN; HUMAN EXPERIMENT; LOW DRUG DOSE; MALE; NORMAL HUMAN; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE;

ADULT; BLOOD CIRCULATION; DRUG ADMINISTRATION ROUTES; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; OSTEOPOROSIS; OSTEOPROTEGERIN; PHARMACOKINETICS;

EID: 34447512931     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH06-11-0671     Document Type: Article

References (46)

1. Griffith GC, Nichols G, Jr., Asher JD, et al. Heparin Osteoporosis. J Am Med Assoc 1965; 193: 91-94.
2. Griffiths HT, Liu DT. Severe heparin osteoporosis in pregnancy. Postgrad Med J 1984; 60: 424-425.
3. Zimran A, Shilo S, Fisher D, et al. Histomorphometric evaluation of reversible heparin-induced osteoporosis in pregnancy. Arch Intern Med 1986; 146: 386-388.
4. Dahlman TC. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 1993; 168: 1265-1270.
5. Hawkins D, Evans J. Minimising the risk of heparin-induced osteoporosis during pregnancy. Expert Opin Drug Saf 2005; 4: 583-590.
6. Murray WJ, Lindo VS, Kakkar VV, et al. Long-term administration of heparin and heparin fractions and osteoporosis in experimental animals. Blood Coagul Fibrinolysis 1995; 6: 113-118.
7. Muir JM, Hirsh J, Weitz JI, et al. A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats. Blood 1997; 89: 3236-3242.
8. Shaughnessy SG, Young E, Deschamps P, et al. The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria. Blood 1995; 86: 1368-1373.
9. Barbour LA, Kick SD, Steiner JF, et al. A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am J Obstet Gynecol 1994; 170: 862-869.
10. Douketis JD, Ginsberg JS, Burrows RF, et al. The effects of long-term heparin therapy during pregnancy on bone density. A prospective matched cohort study. Thromb Haemost 1996; 75: 254-257.
11. Shefras J, Farquharson RG. Bone density studies in pregnant women receiving heparin. Eur J Obstet Gynecol Reprod Biol 1996; 65: 171-174.
12. Pettila V, Leinonen P, Markkola A, et al. Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb Haemost 2002; 87: 182-186.
13. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density. Cell 1997; 89: 309-319.
14. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. PNAS 1998; 95: 3597-3602.
15. Min H, Morony S, Sarosi I, et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 2000; 192: 463-474.
16. Bekker PJ, Holloway D, Nakanishi A, et al. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 2001; 16: 348-360.
17. Body J-J, Greipp P, Coleman RE, et al. A Phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003; 97: 887-892.
18. Body J-J, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-{kappa}B ligand inhibitor, Denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006; 12: 1221-1228.
19. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006; 354: 821-831.
20. Yamaguchi K, Kinosaki M, Goto M, et al. Characterization of structural domains of human osteoclastogenesis inhibitory factor. J Biol Chem 1998; 273: 5117-5123.
21. Standal T, Seidel C, Hjertner O, et al. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood 2002; 100: 3002-3007.
22. Mosheimer BA, Kaneider NC, Feistritzer C, et al. Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes. J Clin Endocrinol Metab 2005; 90: 2964-2971.
23. Theoleyre S, Kwan Tat S, Vasio P, et al. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: Role in the interactions with receptor activator of nuclear factor [kappa]B ligand (RANKL) and RANK. Biochern Biophys Res Commun 2006;347: 460-467.
24. Hansen JB, Sandset PM, Huseby KR, et al. Differential effect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor: evidence for a difference in antithrombotic action. Br J Haematol 1998; 101: 638-646.
25. Tai MM. A mathematical model for the determination of total area under glucose tolerance and other metabolic curves. Diabetes Care 1994; 17: 152-154.
26. Malyankar UM, Scatena M, Suchland KL, et al. Osteoprotegerin Is an alpha vbeta 3-induced, NF-kappa B-dependent Survival Factor for Endothelial Cells. J Biol Chem 2000; 275: 20959-20962.
27. Pritzker LB, Scatena. M, Giachelli CM. The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival. Mol Biol Cell 2004; 15: 2834-2841.
28. Zannettino AC, Holding CA, Diamond P, et al. Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. J Cell Physiol 2005; 204: 714-723.
29. Hansen J-B, Olsen R, Webster P. Association of tissue factor pathway inhibitor with human umbilical vein endothelial cells. Blood 1997; 90: 3568-3578.
30. Lookene A, Chevreuil O, Ostergaard P, et al. Interaction of lipoprotein lipase with heparin fragments and with heparan sulfate: stoichiometry, stabilization, and kinetics. Biochemistry 1996; 35: 12155-12163.
31. Valentin S, Larnkjer A, Ostergaard P, et al. Characterization of the binding between tissue factor pathway inhibitor and glycosaminoglycans. Thromb Res 1994; 75: 173-183.
32. Hansen JB, Sandset PM, Huseby KR, et al. Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in man. Thromb Haemost 1996; 76: 703-709.
33. Lupu C, Poulsen E, Roquefeuil S, et al. Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture. Arterioscler Thromb Vasc Biol 1999; 19: 2251-2262.
34. Brodin E, Svensson B, Paulssen RH, et al. Intravascular release and urinary excretion of tissue factor pathway inhibitor during heparin treatment. J Lab Clin Med 2004; 144: 246-253.
35. Hansen JB, Svensson B, Olsen R, et al. Heparin induces synthesis and secretion of tissue factor pathway inhibitor from endothelial cells in vitro. Thromb Haemost 2000; 83: 937-943.
36. Schneeweis LA, Willard D, Milla ME. Functional dissection of osteoprotegerin and its interaction with receptor activator of NF-kappaB ligand. J Biol Chem 2005; 280: 41155-41164.
37. Tomoyasu A, Goto M, Fujise N, et al. Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor. Biochem Biophys Res Commun 1998; 245: 382-387.
38. Theoleyre S, Wittrant Y, Couillaud S, et al. Cellular activity and signaling induced by osteoprotegerin in osteoclasts: involvement of receptor activator of nuclear factor [kappa]B ligand and MAPK. Biochim Biophys Acta (BBA) - Mol Cell Res 2004; 1644: 1-7.
39. Yang L, Butcher M, Simon RR, et al. The effect of heparin on osteoblast differentiation and activity in primary cultures of bovine aortic smooth muscle cells. Atherosclerosis 2005; 179: 79-86.
40. Bhandari M, Hirsh J, Weitz JI, et al. The effects of standard and low molecular weight heparin on bone nodule formation in vitro. Thromb Haemost 1998; 80: 413-417.
41. Tsuda E, Goto M, Mochizuki S, et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 1997; 234: 137-142.
42. Stilgren LS, Rettmer E, Eriksen EF, et al. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-[kappa]b ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. Bone 2004; 35: 256-265.
43. Shaughnessy SG, Hirsh J, Bhandari M, et al. A histomorphometric evaluation of heparin-induced bone loss after discontinuation of heparin treatment in rats. Blood 1999; 93: 1231-1236.
44. Wawrzynska L, Tomkowski WZ, Przedlacki J, et al. Changes in bone density during long-term administration of low-molecular-weight heparins or acenocoumarol for secondary prophylaxis of venous thromboembolism. Pathophysiol Haemost Thromb 2003; 33: 64-67.
45. Fu Q, Jilka RL, Manolagas SC, et al. Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. J Biol Chem 2002; 277: 48868-48875.
46. Thomas T. Intermittent parathyroid hormone therapy to increase bone formation. Joint Bone Spine 2006; 73: 262-269.